AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32419559 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of biotin interference with other tests
Number of subjects: 149
Study 32419559 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians asking patients to discontinue biotin before testing
Number of subjects: 149
Study 33439250 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (open reduction and internal fixation using a volar-locking plate)
Number of subjects: 166
Study 33439250 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment (closed reduction and cast immobilization)
Number of subjects: 166
Study 35331961 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (HFAF‐trained group; n = 13)
Number of subjects: 26
Study 35331961 — intervention group
Group type: COMPARATOR
Intervention: No training (HFAF‐untrained group; n = 13)
Number of subjects: 26
Study 32615637 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 0
Study 32615637 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection (TUR)
Number of subjects: 0
Study 34435205 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics score based on pericoronary adipose tissue (PCAT)
Number of subjects: 1586
Study 34435205 — intervention group
Group type: COMPARATOR
Intervention: Plaque score based on conventional plaque characteristics
Number of subjects: 1586
Study 34435205 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated score
Number of subjects: 1586
Study 35019219 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm ultrashort implants
Number of subjects: 80
Study 35019219 — intervention group
Group type: COMPARATOR
Intervention: 10-mm long implants in augmented bone
Number of subjects: 80
Study 32646563 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus- and probucol-eluting stents
Number of subjects: 3002
Study 32646563 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer zotarolimus-eluting stents
Number of subjects: 3002
Study 35357606 — intervention group
Group type: EXPERIMENTAL
Intervention: CultActive treatment (A23187 ionophore), 122 MII oocytes treated
Number of subjects: 247
Study 35357606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment), 125 MII oocytes
Number of subjects: 247
Study 35357606 — intervention group
Group type: EXPERIMENTAL
Intervention: CultActive treatment (A23187 ionophore)
Number of subjects: 247
Study 35357606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 247
Study 34168003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral administration of ipilimumab (IPI) 10 mg (cohort-1)
Number of subjects: 27
Study 34168003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral administration of ipilimumab (IPI) 5 mg plus nivolumab (NIVO) 10 mg (cohort-2)
Number of subjects: 27
Study 34168003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of nivolumab (NIVO) 10 mg, repeated every 2 weeks (max. five administrations)
Number of subjects: 27
Study 34168003 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort comparison
Number of subjects: 27
Study 33099227 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (1.4 mg every other day)
Number of subjects: 37
Study 33099227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 36484590 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 242
Study 36484590 — intervention group
Group type: COMPARATOR
Intervention: Education intervention
Number of subjects: 242
Study 36484590 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional PTSD unremitted at 3 months
Number of subjects: 242
Study 35249543 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised study invitation letter
Number of subjects: 509
Study 35249543 — intervention group
Group type: COMPARATOR
Intervention: Non-personalised study invitation letter
Number of subjects: 509
Study 34064069 — intervention group
Group type: EXPERIMENTAL
Intervention: WLPB (Weight Loss Program with Bryndza cheese, 30 g daily)
Number of subjects: 22
Study 34064069 — intervention group
Group type: COMPARATOR
Intervention: WLP (Weight Loss Program without Bryndza cheese)
Number of subjects: 22
Study 36322154 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro Tooth Crème 0.21% Sodium Fluoride Anti‐Cavity Paste with functional‐Tri Calcium Phosphate (f‐TCP)
Number of subjects: 105
Study 36322154 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Varnish with RECALDENT™ (CPP‐ACP)
Number of subjects: 105
Study 36322154 — intervention group
Group type: COMPARATOR
Intervention: Home‐care group (control)
Number of subjects: 105
Study 33245999 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanillin (pleasant odour)
Number of subjects: 60
Study 33245999 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioglycolic acid (TGA, unpleasant odour)
Number of subjects: 60
Study 33245999 — intervention group
Group type: COMPARATOR
Intervention: Odourless control condition
Number of subjects: 60
Study 33551021 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong Baduanjin intervention (22 weeks)
Number of subjects: 186
Study 33551021 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 186
Study 33551021 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong Baduanjin intervention
Number of subjects: 186
Study 34166834 — intervention group
Group type: COMPARATOR
Intervention: GDC-3280 (25–1600 mg single dose)
Number of subjects: 80
Study 34166834 — intervention group
Group type: COMPARATOR
Intervention: GDC-3280 (200 mg or 275 mg twice daily for 7 days)
Number of subjects: 80
Study 34166834 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-3280 (400 mg and 800 mg single dose with food)
Number of subjects: 80
Study 34166834 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-3280 (400 mg and 800 mg single dose)
Number of subjects: 80
Study 34166834 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-3280 (repeat doses)
Number of subjects: 80
Study 34166834 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-3280 (single doses)
Number of subjects: 80
Study 34166834 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-3280 with rabeprazole
Number of subjects: 80
Study 33826736 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher degree of self-reported or accelerometer-determined moderate-to-vigorous physical activity
Number of subjects: 329758
Study 33826736 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer time spent watching television
Number of subjects: 329758
Study 33826736 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to a higher degree of physical activity
Number of subjects: 329758
Study 33826736 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted television watching duration
Number of subjects: 329758
Study 32936053 — intervention group
Group type: EXPERIMENTAL
Intervention: Listeners higher in dispositional emotional empathy
Number of subjects: 140
Study 32936053 — intervention group
Group type: EXPERIMENTAL
Intervention: Listeners higher in emotional empathy
Number of subjects: 140
Study 32936053 — intervention group
Group type: EXPERIMENTAL
Intervention: Listeners higher in emotional empathy with accurate emotion ratings
Number of subjects: 140
Study 32475262 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-spent culture medium
Number of subjects: 318
Study 32475262 — intervention group
Group type: COMPARATOR
Intervention: New pre-equilibrated culture media
Number of subjects: 318
Study 35654691 — intervention group
Group type: EXPERIMENTAL
Intervention: encorafenib + cetuximab
Number of subjects: 441
Study 35654691 — intervention group
Group type: COMPARATOR
Intervention: ACT/control (cetuximab + irinotecan‐based chemotherapy)
Number of subjects: 441
Study 33106389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group from IMPACT and ASCEND trials)
Number of subjects: 0
Study 32384122 — intervention group
Group type: EXPERIMENTAL
Intervention: Encala™ treatment
Number of subjects: 66
Study 32384122 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 66
Study 36262803 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormone therapy (NHT) with anastrozole for at least six months (menopausal patients) or anastrozole with subcutaneous goserelin acetate every 12 weeks for at least six months (premenopausal women).
Number of subjects: 130
Study 36262803 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NCT) with a standard institutional regimen based on anthracyclines and taxanes.
Number of subjects: 130
Study 34119409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention bundle (vitamin C sprays, peppermint water mouthwash, lip moisturiser)
Number of subjects: 61
Study 34119409 — intervention group
Group type: COMPARATOR
Intervention: Placebo interventions (saline sprays, 40 °C water mouthwash, wetting lips with water)
Number of subjects: 61
Study 32591901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (1 mg/kg)
Number of subjects: 184
Study 32591901 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (0.1 mg/kg)
Number of subjects: 184
Study 35732396 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Group 1 - smart electronic toothbrush, educational booklet
Number of subjects: 0
Study 35732396 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Group 2 - smart electronic toothbrush, educational booklet, oral hygiene care skill assessment, personalised oral hygiene instruction and treatment plan, in-home and telephone coaching on behaviour change
Number of subjects: 0
Study 35732396 — intervention group
Group type: COMPARATOR
Intervention: Control Group - educational booklet
Number of subjects: 0
Study 33498165 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 129
Study 33498165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 35551845 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of cannabidiol
Number of subjects: 11
Study 35551845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 35348435 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality-induced hypnosis
Number of subjects: 153
Study 35348435 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality for distraction
Number of subjects: 153
Study 35348435 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study 33199596 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomy
Number of subjects: 0
Study 35411554 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Number of subjects: 140000
Study 35411554 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT
Number of subjects: 140000
Study 35411554 — intervention group
Group type: COMPARATOR
Intervention: Demographic and socioeconomic factors
Number of subjects: 140000
Study 35411554 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy after positive FIT
Number of subjects: 140000
Study 32151503 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy (mCIMT), 1 hour therapy sessions for 14 consecutive days, normal arm constrained for 6 hours per day.
Number of subjects: 39
Study 32151503 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program (control group).
Number of subjects: 39
Study 37277418 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral micronized progesterone at bedtime for 3 months
Number of subjects: 189
Study 37277418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 33549036 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg with a 240 mg loading dose
Number of subjects: 0
Study 33549036 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 0
Study 33549036 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (both dosages)
Number of subjects: 0
Study 33549036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32038017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solutions enriched with maltodextrin
Number of subjects: 0
Study 32038017 — intervention group
Group type: COMPARATOR
Intervention: Standard fasting protocols
Number of subjects: 0
Study 32038017 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-enriched drinks
Number of subjects: 0
Study 35316790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pole Walking (PW) at maximal effort (PWmax)
Number of subjects: 15
Study 35316790 — intervention group
Group type: COMPARATOR
Intervention: Walking without poles (W) at maximal effort (Wmax)
Number of subjects: 15
Study 35316790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pole Walking (PW) at 80% effort (PW80)
Number of subjects: 15
Study 35316790 — intervention group
Group type: COMPARATOR
Intervention: Walking without poles (W) at 80% effort (W80)
Number of subjects: 15
Study 32993815 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral prednisolone 0.5 mg/kg and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral prednisolone 0.5 mg/kg and omeprazole 20 mg daily for 3 days.
Number of subjects: 400
Study 32993815 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral placebo and omeprazole 20 mg daily for 3 days.
Number of subjects: 400
Study 33747373 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual surgical information (video clip)
Number of subjects: 50
Study 33747373 — intervention group
Group type: COMPARATOR
Intervention: Regular information only (Control)
Number of subjects: 50
Study 32631261 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT-OCD (n = 40)
Number of subjects: 80
Study 32631261 — intervention group
Group type: COMPARATOR
Intervention: Care as usual control group (n = 40)
Number of subjects: 80
Study 35410282 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and advice
Number of subjects: 16
Study 35410282 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and advice plus prefabricated orthoses
Number of subjects: 16
Study 35410282 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and advice plus custom made orthoses
Number of subjects: 16
Study 34684562 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA supplementation (1.6 g of EPA and DHA per day for 12 weeks)
Number of subjects: 78
Study 34684562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 33438783 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment-based cognitive behavioural therapy for insomnia
Number of subjects: 60
Study 33438783 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 32573767 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual animation (3 minutes)
Number of subjects: 172
Study 32573767 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 172
Study 34595827 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg daily
Number of subjects: 44
Study 34595827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 33826754 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 965
Study 33826754 — intervention group
Group type: COMPARATOR
Intervention: Completion lymph node dissection (CLND)
Number of subjects: 965
Study 33826754 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 965
Study 33826754 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance and CLND
Number of subjects: 965
Study 32886113 — intervention group
Group type: EXPERIMENTAL
Intervention: apo-Lf + FeSO4
Number of subjects: 25
Study 32886113 — intervention group
Group type: COMPARATOR
Intervention: FeSO4
Number of subjects: 25
Study 32886113 — intervention group
Group type: COMPARATOR
Intervention: holo-Lf
Number of subjects: 25
Study 35078086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraction number line game
Number of subjects: 188
Study 35078086 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaffolded fraction number line games
Number of subjects: 188
Study 35078086 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 188
Study 34939180 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study 34939180 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative quantitative techniques
Number of subjects: 0
Study 35354006 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP training
Number of subjects: 190
Study 32417348 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 Gy/35F with IMRT (Arm B)
Number of subjects: 188
Study 32417348 — intervention group
Group type: COMPARATOR
Intervention: 70 Gy/35F in 7 weeks with 3D-RT (Arm A)
Number of subjects: 188
Study 32417348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose‐escalated IMRT
Number of subjects: 188
Study 35397249 — intervention group
Group type: EXPERIMENTAL
Intervention: SWITCH group (monotherapy with either FGA or SGA)
Number of subjects: 136
Study 35397249 — intervention group
Group type: COMPARATOR
Intervention: STAY group (combination treatment of FGA and SGA)
Number of subjects: 136
Study 34929667 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-initiated Kangaroo Mother Care (ciKMC)
Number of subjects: 200
Study 34929667 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 32696522 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept (0.2-1.25 mg/kg, subcutaneously once every 3 weeks)
Number of subjects: 285
Study 32696522 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept (1 mg/kg starting dose)
Number of subjects: 285
Study 32696522 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept (0.2-1.25 mg/kg)
Number of subjects: 285
Study 32696522 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 285
Study 33196937 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone treatment
Number of subjects: 225
Study 33196937 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cocaine use at baseline
Number of subjects: 225
Study 33166594 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 % silver nitrate (AgNO3) solution followed by 5 % sodium fluoride (NaF) varnish
Number of subjects: 1070
Study 33166594 — intervention group
Group type: COMPARATOR
Intervention: 38 % silver diamine fluoride (SDF) solution followed by placebo varnish
Number of subjects: 1070
Study 34494957 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 996
Study 34494957 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 996
Study 34494957 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg no load
Number of subjects: 996
Study 34494957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 996
Study 35947082 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 ml 2% mepivacaine hydrochloride with 1:100,000 adrenalin
Number of subjects: 330
Study 35947082 — intervention group
Group type: COMPARATOR
Intervention: 3.4 ml 4% articaine hydrochloride with 1:100,000 adrenalin
Number of subjects: 330
Study 34722430 — intervention group
Group type: EXPERIMENTAL
Intervention: SS group (simplified external cardiac massage trainer)
Number of subjects: 60
Study 34722430 — intervention group
Group type: EXPERIMENTAL
Intervention: RA group (Resusci Anne manikin)
Number of subjects: 60
Study 34722430 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional simulation training with instructor feedback)
Number of subjects: 60
Study 34722430 — intervention group
Group type: EXPERIMENTAL
Intervention: SS group
Number of subjects: 60
Study 34722430 — intervention group
Group type: EXPERIMENTAL
Intervention: RA group
Number of subjects: 60
Study 34015465 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generation (SG) format
Number of subjects: 48
Study 34015465 — intervention group
Group type: COMPARATOR
Intervention: Multiple-choice (MCQ) format
Number of subjects: 48
Study 33048572 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lapse cigarette
Number of subjects: 54
Study 33048572 — intervention group
Group type: COMPARATOR
Intervention: No-lapse control condition
Number of subjects: 54
Study 35988083 — intervention group
Group type: COMPARATOR
Intervention: Olfactory training (daily sessions for 3 months)
Number of subjects: 35
Study 34036519 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% human albumin
Number of subjects: 308
Study 34036519 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 308
Study 33349581 — intervention group
Group type: EXPERIMENTAL
Intervention: istradefylline
Number of subjects: 0
Study 33349581 — intervention group
Group type: COMPARATOR
Intervention: preladenant
Number of subjects: 0
Study 33349581 — intervention group
Group type: COMPARATOR
Intervention: tozadenant
Number of subjects: 0
Study 32275360 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic moxibustion
Number of subjects: 59
Study 32275360 — intervention group
Group type: COMPARATOR
Intervention: Placebo moxibustion
Number of subjects: 59
Study 35592965 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-autonomous AI application promoting dental recall visits
Number of subjects: 224
Study 35105573 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (SUG)
Number of subjects: 99
Study 34195582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosponge-TFF3 screening
Number of subjects: 0
Study 34195582 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35500264 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly subcutaneous semaglutide
Number of subjects: 0
Study 35500264 — intervention group
Group type: COMPARATOR
Intervention: Daily liraglutide
Number of subjects: 0
Study 34353646 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape placed over the face mask at the bridge of the nose
Number of subjects: 123
Study 34353646 — intervention group
Group type: COMPARATOR
Intervention: No tape over the mask/nose (Control)
Number of subjects: 123
Study 34353646 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-provided masks
Number of subjects: 123
Study 32627595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 12